Who
Christopher R. Fenimore
EVP Finance CFO
Company insider
Files Form 4 as: EVP Finance CFO, Regeneron Pharmaceuticals.
In numbers
- Trades disclosed
- 197
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $30.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Dec 2017
- Last trade
- 18 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 20 Aug 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $2.4M6,283 at $381.92 | filing |
| 18 Aug 2026filed 20 Aug 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $3.7M4,599 at $813.47 | filing |
| 18 Aug 2026filed 20 Aug 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,283 at $0.00 | filing |
| 18 Aug 2026filed 20 Aug 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,283 at $0.00 | filing |
| 18 Aug 2026filed 20 Aug 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $2.4M6,283 at $381.92 | filing |
| 18 Aug 2026filed 20 Aug 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $3.7M4,599 at $813.47 | filing |
| 8 Dec 2025filed 9 Dec 2025 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $707K992 at $712.94 | filing |
| 5 Dec 2025filed 9 Dec 2025 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,924 at $0.00 | filing |
| 5 Dec 2025filed 9 Dec 2025 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —3,027 at $0.00 | filing |
| 16 Dec 2024filed 18 Dec 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $359K491 at $730.81 | filing |
| 9 Dec 2024filed 10 Dec 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $897K1,140 at $787.00 | filing |
| 6 Dec 2024filed 10 Dec 2024 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,979 at $0.00 | filing |
| 6 Dec 2024filed 10 Dec 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —2,591 at $0.00 | filing |
| 28 Aug 2024filed 29 Aug 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $275K228 at $1,204.79 | filing |
| 28 Aug 2024filed 29 Aug 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $923K766 at $1,205.44 | filing |
| 28 Aug 2024filed 29 Aug 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $241K200 at $1,206.30 | filing |
| 28 Aug 2024filed 29 Aug 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2.7M2,237 at $1,204.71 | filing |
| 28 Aug 2024filed 29 Aug 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.1M928 at $1,205.49 | filing |
| 28 Aug 2024filed 29 Aug 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $543K450 at $1,206.15 | filing |
| 28 Aug 2024filed 29 Aug 2024 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $285K236 at $1,205.67 | filing |
News
1,598 Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Perpetual LtdREGN · dailypolitical.com · 15 Oct 2026Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Up 3.6% – Here's What HappenedREGN · dailypolitical.com · 14 Oct 2026Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $780.00REGN · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name Christopher R. Fenimore; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.